Mortality of New York children with sickle cell disease identified through newborn screening

被引:20
作者
Wang, Ying [1 ,2 ]
Liu, Gang [1 ]
Caggana, Michele [1 ,3 ]
Kennedy, Joseph
Zimmerman, Regina [4 ]
Oyeku, Suzette O. [5 ]
Werner, Ellen M. [6 ]
Grant, Althea M. [7 ]
Green, Nancy S. [8 ]
Grosse, Scott D. [7 ]
机构
[1] SUNY Albany, Sch Publ Hlth, Albany, NY 12222 USA
[2] New York State Dept Hlth, Div Data Management & Res, Off Primary Care & Hlth Management Syst, Albany, NY USA
[3] New York State Dept Hlth, Wadsworth Ctr, Newborn Screening Program, Albany, NY USA
[4] New York City Dept Hlth & Mental Hyg, Off Vital Stat, New York, NY USA
[5] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, New York, NY USA
[6] NHLBI, Div Blood Dis & Resources, Bethesda, MD 20892 USA
[7] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA USA
[8] Columbia Univ, Med Ctr, Dept Pediat, New York, NY USA
关键词
long-term follow-up; maternal race/ethnicity; mortality; newborn screening; sickle cell disease; TERM-FOLLOW-UP; UNITED-STATES; 1ST DECADE; HYDROXYUREA; ANEMIA; ADOLESCENTS; DISORDERS; SURVIVAL; INFANTS; RISK;
D O I
10.1038/gim.2014.123
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: Long-term follow-up of newborn screening for conditions such as sickle cell disease can be conducted using linkages to population-based data. We sought to estimate childhood sickle cell disease mortality and risk factors among a statewide birth cohort with sickle cell disease identified through newborn screening. Methods: Children with sickle cell disease identified by newborn screening and born to New York residents in 2000-2008 were matched to birth and death certificates. Mortality rates were calculated (using numbers of deaths and observed person-years at risk) and compared with mortality rates for all New York children by maternal race/ethnicity. Stratified analyses were conducted to examine associations between selected factors and mortality. Results: Among 1,911 infants with sickle cell disease matched to birth certificates, 21 deaths were identified. All-cause mortality following diagnosis was 3.8 per 1,000 person-years in the first 2 years of life and 1.0 per 1,000 person-years at ages 2-9 years. The mortality rate was significantly lower among children of foreign-born mothers and was significantly higher among preterm infants with low birth weight. The mortality rates were not significantly higher for infants after 28 days with sickle cell disease than for all New York births, but they were 2.7-8.4 times higher for children 1 through 9 years old with homozygous sickle cell disease than for those of all non-Hispanic black or Hispanic children born to New York residents. Conclusion: Estimated mortality risk in children with homozygous sickle cell disease remains elevated even after adjustment for maternal race/ethnicity. These results provide evidence regarding the current burden of child mortality among children with sickle cell disease despite newborn screening.
引用
收藏
页码:452 / 459
页数:8
相关论文
共 40 条
  • [1] Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life
    Adamkiewicz, Thomas V.
    Silk, Benjamin J.
    Howgate, James
    Baughman, Wendy
    Strayhorn, Gregory
    Sullivan, Kevin
    Farley, Monica M.
    [J]. PEDIATRICS, 2008, 121 (03) : 562 - 569
  • [2] [Anonymous], HEM MON
  • [3] History and Current Status of Newborn Screening for Hemoglobinopathies
    Benson, Jane M.
    Therrell, Bradford L., Jr.
    [J]. SEMINARS IN PERINATOLOGY, 2010, 34 (02) : 134 - 144
  • [4] The number of people with sickle-cell disease in the United States: National and state estimates
    Brousseau, David C.
    Panepinto, Julie A.
    Nimmer, Mark
    Hoffmann, Raymond G.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (01) : 77 - 78
  • [5] Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P169
  • [6] EFFECT OF HYDROXYUREA ON THE FREQUENCY OF PAINFUL CRISES IN SICKLE-CELL-ANEMIA
    CHARACHE, S
    TERRIN, ML
    MOORE, RD
    DOVER, GJ
    BARTON, FB
    ECKERT, SV
    MCMAHON, RP
    BONDS, DR
    ORRINGER, E
    JONES, S
    STRAYHORN, D
    ROSSE, W
    PHILLIPS, G
    PEACE, D
    JOHNSONTELFAIR, A
    MILNER, P
    KUTLAR, A
    TRACY, A
    BALLAS, SK
    ALLEN, GE
    MOSHANG, J
    SCOTT, B
    STEINBERG, M
    ANDERSON, A
    SABAHI, V
    PEGELOW, C
    TEMPLE, D
    CASE, E
    HARRELL, R
    CHILDERIE, S
    EMBURY, S
    SCHMIDT, B
    DAVIES, D
    KOSHY, M
    TALISCHYZAHED, N
    DORN, L
    PENDARVIS, G
    MCGEE, M
    TELFER, M
    DAVIS, A
    CASTRO, O
    FINKE, H
    PERLIN, E
    SITEMAN, J
    GASCON, P
    DIPAOLO, P
    GARGIULO, S
    ECKMAN, J
    BAILEY, JH
    PLATT, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) : 1317 - 1322
  • [7] What is the evidence that hydroxyurea improves health-related quality of life in patients with sickle cell disease?
    Darbari, Deepika S.
    Panepinto, Julie A.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, : 290 - 291
  • [8] National trends in the mortality of children with sickle cell disease, 1968 through 1992
    Davis, H
    Schoendorf, KC
    Gergen, PJ
    Moore, RM
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1997, 87 (08) : 1317 - 1322
  • [9] Frempong Tamiesha, 2007, Conn Med, V71, P9
  • [10] Sickle cell disease: old discoveries, new concepts, and future promise
    Frenette, Paul S.
    Atweh, George F.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (04) : 850 - 858